FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION
Ask a doctor about a prescription for FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION
How to use FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION
Introduction
Package Leaflet: Information for the User
Fasturtec 1.5mg/ml powder and solvent for concentrate for solution for infusion
rasburicase
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, nurse or hospital pharmacist.
- If you get any side effects, talk to your doctor, nurse or hospital pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack:
- What is Fasturtec and what is it used for
- What you need to know before you use Fasturtec
- How to use Fasturtec
- Possible side effects
- Storage of Fasturtec
- Contents of the pack and other information
1. What is Fasturtec and what is it used for
Fasturtec contains the active substance rasburicase.
Rasburicase is used to treat or prevent high levels of uric acid in the blood that occur in adults, children and adolescents (from 0 to 17 years) with blood cell disorders (haematological disorders) who are going to receive or are receiving chemotherapy.
When chemotherapy is given, cancer cells are destroyed, releasing large amounts of uric acid into the bloodstream.
Fasturtec works by helping the body get rid of uric acid through the kidneys.
2. What you need to know before you use Fasturtec
Do not use Fasturtec:
- if you have a history of haemolytic anaemia(a disease caused by abnormal destruction of red blood cells).
Warnings and precautions
Tell your doctor, nurse or hospital pharmacist if you have a history of any type of allergy.
Tell your doctor if you have ever had any type of allergic reaction to other medicines; Fasturtec may cause allergic reactions such as severe anaphylaxis including anaphylactic shock (potentially fatal or life-threatening allergic reactions).
Tell your doctor immediatelyif you notice any of the following symptoms and may need to stop treatment:
- swelling of the face, lips, tongue or throat
- cough or wheezing
- difficulty breathing or swallowing
- skin rash, itching or hives (irritation-type rash) on the skin
These could be the first symptoms of a severe allergic reaction. You may need to stop your treatment with Fasturtec, and you may need additional treatments.
It is not known if the risk of developing an allergic reaction increases if treatment with Fasturtec is repeated.
If blood disorders occur in which red blood cells are abnormally destroyed (haemolysis) or abnormal levels of blood pigments (methaemoglobinemia) occur, your doctor will immediately and permanently stop treatment with Fasturtec.
Using Fasturtec with other medicines
Tell your doctor if you are using or have recently used any other medicines, including those obtained without a prescription.
Pregnancy and breast-feeding
Tell your doctor if you are pregnant or think you may be pregnant, or if you are breast-feeding.
Driving and using machines
There is no information available on the ability to drive and use machines.
Fasturtec contains sodium
This medicine contains up to 10.5 mg of sodium (from cooking/table salt) per vial. This is equivalent to 0.53% of the maximum recommended daily intake of sodium for an adult.
3. How to use Fasturtec
Fasturtec will be given to you before or during your chemotherapy treatment.
Fasturtec is injected slowly into a vein over about 30 minutes.
Your dose will be calculated according to your body weight.
The recommended dose is 0.20 mg per kg of body weight and day, in both children and adults.
It will be given once a day, for up to 7 days.
During treatment with Fasturtec, your doctor will perform blood tests to check uric acid levels and decide how long your treatment will last.
Your doctor may also perform blood tests to make sure you do not develop any blood disorders.
If you use more Fasturtec than you should
If this happens, your doctor will perform a rigorous periodic check of red blood cells in the blood and treat any symptoms that appear.
If you have any further questions on the use of this medicine, ask your doctor, nurse or hospital pharmacist.
4. Possible side effects
Like all medicines, Fasturtec can cause side effects, although not everybody gets them.
Fasturtec will be given to you at the same time as other medicines that may also cause side effects.
If you suddenly notice:
- swelling of the face, lips, tongue or other parts of your body
- difficulty breathing, wheezing or breathing problems
- skin rash, itching or hives.
Tell your doctor, nurse or hospital pharmacist immediately, as these symptoms can be a sign of a severe allergic reaction (anaphylaxis). These effects occur rarely (may affect up to 1 in 1,000 patients).
Very common side effects (may affect more than 1 in 10 people):
- diarrhoea
- vomiting
- nausea
- headache
- fever.
Common side effects (may affect up to 1 in 10 patients):
- allergic reactions, mainly skin rashes and hives.
Uncommon side effects (may affect up to 1 in 100 patients):
- severe hypersensitivity reactions, such as anaphylaxis (rare) including anaphylactic shock (frequency not known) which could be fatal
- low blood pressure (hypotension)
- wheezing or breathing difficulties (bronchospasm)
- blood disorders such as problems where red blood cells are abnormally destroyed (haemolysis), destroyed (haemolytic anaemia), or abnormal levels of blood pigments (methaemoglobinemia)
- seizures (convulsions).
Rare side effects (may affect up to 1 in 1,000 patients):
- runny nose or nasal congestion, sneezing, facial pressure or pain (rhinitis).
Frequency not known (cannot be estimated from the available data):
- involuntary muscle movements (involuntary muscle contraction).
If you notice any of these side effects, tell your doctor, nurse or hospital pharmacist.
Reporting of side effects
If you experience any side effects, talk to your doctor, nurse or hospital pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Fasturtec
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
Store in a refrigerator (2°C - 8°C).
Do not freeze.
Store in the original package to protect from light.
Do not use this medicine if you notice that the solution is not clear and/or contains particles.
6. Contents of the pack and other information
What is in Fasturtec
- The active substance is rasburicase 1.5 mg/ml. Rasburicase is produced by genetic engineering in a microorganism called Saccharomyces cerevisiae.
- The other ingredients of the powder are: alanine, mannitol, disodium phosphate dodecahydrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate.
- The other ingredients of the solvent are: poloxamer 188, water for injections.
Appearance and packaging
Fasturtec is presented as a powder for concentrate for solution for infusion (sterile concentrate powder) with a solvent.
The powder is white or almost white, agglomerated or not.
The solvent is a clear and colourless liquid.
Pack with 3 vials of 1.5 mg of rasburicase and 3 ampoules of 1 ml of solvent. The powder is presented in 2 ml or 3 ml glass vials with a rubber stopper and the solvent in a 2 ml glass ampoule.
Pack with 1 vial of 7.5 mg of rasburicase and 1 ampoule of 5 ml of solvent. The powder is presented in 10 ml glass vials with a rubber stopper and the solvent in a 5 ml glass ampoule.
Not all pack sizes may be marketed.
Marketing authorisation holder
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
Manufacturers
Sanofi S.r.l.
Via Valcanello, 4
03012 Anagni (FR)
Italy
You can request more information about this medicine from the local representative of the marketing authorisation holder.
België/Belgique/ Belgien Sanofi Belgium Tél/Tel: +32 (0)2 710 54 00 | Luxembourg/Luxemburg Sanofi Belgium Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien) |
| Magyarország sanofi-aventis zrt., Magyarország Tel.: +36 1 505 0050 |
Ceská republika Sanofi s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Danmark Sanofi A/S Tlf: +45 45 16 70 00 | Nederland Sanofi B.V. Tel: +31 20 245 4000 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel.: 0800 04 36 996 Tel. from abroad: +49 69 305 70 13 | Norge sanofi-aventis Norge AS Tlf: +47 67 10 71 00 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Österreich sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
Ελλάδα sanofi-aventis AEBE Τηλ: +30 210 900 16 00 | Polska Sanofi sp. z o.o Tel.: +48 22 280 00 00 |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi - Produtos Farmacêuticos, Lda. Tel: +351 21 35 89 400 |
France Sanofi Winthrop Industrie Tél: 0 800 222 555 Appel depuis l’étranger : +33 1 57 63 23 23 Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | România Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia sanofi S.r.l. Tel 800.536389 | Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 |
Κύπρος C.A. Papaellinas Ltd. Τηλ: +357 22 741741 | Sverige Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvija Swixx Biopharma SIA Tel: +371 6 616 47 50 | United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
---------------------------------------------------------------------------------------------------------------------------
The following information is intended only for healthcare professionals:
See section 3 “How to use Fasturtec” and the practical information on preparation and handling described below.
Fasturtec should be reconstituted with the full volume of the supplied solvent (i.e. the vial of 1.5 mg of rasburicase should be reconstituted with the 1 ml ampoule of solvent; the vial of 7.5 mg of rasburicase should be reconstituted with the 5 ml ampoule of solvent). After reconstitution, a solution with a concentration of 1.5 mg/ml of rasburicase is obtained, which should be further diluted with a 9 mg/ml sodium chloride solution (0.9%).
Reconstitution of the solution:
Add the contents of one ampoule of solvent to a vial containing rasburicase and mix by gently rotating under controlled and validated aseptic conditions.
Do not shake.
Inspect visually before use. Only clear and colourless solutions without particles should be used.
For single use only, any unused solution should be discarded.
The solvent does not contain any preservative. Therefore, the reconstituted solution should be diluted under controlled and validated aseptic conditions.
Dilution before infusion:
The required volume of reconstituted solution depends on the patient's body weight. It may be necessary to use several vials to obtain the required amount of rasburicase for an administration. The required volume of reconstituted solution, obtained from one or several vials, should be further diluted with a 9 mg/ml sodium chloride solution (0.9%) to obtain a total volume of 50 ml. The concentration of rasburicase of the final infusion solution depends on the patient's body weight.
The reconstituted solution does not contain any preservative. Therefore, the diluted solution should be infused immediately.
Infusion:
The final solution should be infused over 30 minutes.
Sample handling:
If it is necessary to monitor a patient's uric acid level, a strict sample handling procedure should be followed in order to minimize ex vivodegradation of the analyte. Blood should be placed in pre-cooled tubes containing heparin as an anticoagulant. Samples should be immersed in an ice/water bath. Plasma samples should be prepared immediately by centrifugation in a pre-cooled centrifuge (4°C). Finally, the plasma should be kept in an ice/water bath and the uric acid level should be analyzed within 4 hours.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTIONDosage form: INJECTABLE INFUSION, UnknownActive substance: rasburicaseManufacturer: Sanofi Winthrop IndustriePrescription requiredDosage form: INJECTABLE PERFUSION, DEXRAZOXANE (D.O.E) 500 MGActive substance: dexrazoxaneManufacturer: Cnx Therapeutics Ireland LimitedPrescription requiredDosage form: INJECTABLE, 350 mgActive substance: calcium folinateManufacturer: Altan Pharmaceuticals SaPrescription required
Alternatives to FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION in Poland
Alternative to FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION in Ukraine
Online doctors for FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for FASTURTEC 1.5 mg/ml POWDER AND SOLVENT FOR CONCENTRATE FOR PERFUSION SOLUTION – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
